WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Search Results

Now showing 1 - 3 of 3
  • Item
    Primary Pulmonary Malignant Fibrous Histiocytoma
    (AVES, 2017-01-01) Cosgun, Tugba; Tezel, Yelda; Akyil, Mustafa; Kolbas, Ilker; Sen, Aycim; Tezel, Cagatay
    Malignant fibrous histiocytoma (MFH) cases are classified within the group of nonclassified sarcomas. The etiopathogenesis is unclear
  • Thumbnail Image
    Item
    Ciliated muconodular papillary tumor masked by COVID-19 infection and aspergilloma
    (BAYCINAR MEDICAL PUBL-BAYCINAR TIBBI YAYINCILIK, 2022-01-01) Cosgun, Tugba; Zeren, Handan; Kocatuerk, Celalettin
    Novel coronavirus disease-2019 (COVID-19) continues to pose a threat all over the world with the effect of new variants. The frequency of other secondary infections such as aspergilloma in patients with COVID-19 disease is not uncommon. Extremely rare lesions such as ciliated muconodular papillary tumor can be masked by radiological images caused by COVID-19 infection or secondary pathologies associated with it, leading to difficulties in diagnosis. Herein, we report a case in whom a diagnosis of aspergilloma and ciliated muconodular papillary tumor after six months of COVID-19 infection was made.
  • Item
    Ex-vivo Lung Perfusion and Its Role in Experimental Studies
    (WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2017-01-01) Cosgun, Tugba; Dabak, Gul; Senbaklavaci, Omer
    Lung transplantation is an accepted treatment modality for end-stage lung diseases. However, the donor pool is not getting larger in comparison to the number of patients on the waiting list. Of the patients on the waiting list for lung transplant, more than a quarter dies while waiting. Utilization of marginal donors became an issue, and ex-vivo lung perfusion (EVLP) was started to be performed to solve this problem. Besides that, success in lung transplantation has not reached a satisfactory level for various reasons including ischemia reperfusion injury. Treatment options against these reasons that cause low success of lung transplantations are being investigated by many centers. Nowadays, EVLP that was initially developed to re-evaluate marginal donors has become a method for studies in experimental models. In our article, we want to review EVLP models in experimental studies.